Synthetic and Natural Derivatives of Cannabidiol.

Spread the love

. 2021;1297:11-25.

doi: 10.1007/978-3-030-61663-2_2.

Affiliations

Item in Clipboard

Paula Morales et al. Adv Exp Med Biol. 2021.

Abstract

The non-psychoactive component of Cannabis Sativa, cannabidiol (CBD), has centered the attention of a large body of research in the last years. Recent clinical trials have led to the FDA approval of CBD for the treatment of children with drug-resistant epilepsy. Even though it is not yet in clinical phases, its use in sleep-wake pathological alterations has been widely demonstrated.Despite the outstanding current knowledge on CBD therapeutic effects in numerous in vitro and in vivo disease models, diverse questions still arise from its molecular pharmacology. CBD has been shown to modulate a wide variety of targets including the cannabinoid receptors, orphan GPCRs such as GPR55 and GPR18, serotonin, adenosine, and opioid receptors as well as ligand-gated ion channels among others. Its pharmacology is rather puzzling and needs to be further explored in the disease context.Also, the metabolism and interactions of this phytocannabinoid with other commercialized drugs need to be further considered to elucidate its clinical potential for the treatment of specific pathologies.Besides CBD, natural and synthetic derivatives of this chemotype have also been reported exhibiting diverse functional profiles and providing a deeper understanding of the potential of this scaffold.In this chapter, we analyze the knowledge gained so far on CBD and its analogs specially focusing on its molecular targets and metabolic implications. Phytogenic and synthetic CBD derivatives may provide novel approaches to improve the therapeutic prospects offered by this promising chemotype.

Keywords: Cannabidiol; Cannabidiol analog; Cannabidiol derivative; Cannabinoid; Sleep; Synthetic cannabidiol.

References

    1. Ahrens J, Demir R, Leuwer M et al (2009) The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-beta glycine receptor function. Pharmacology 83:217–222. https://doi.org/10.1159/000201556 DOI PubMed
    1. Al Suleimani YM, Al Mahruqi AS, Hiley CR (2015) Cardiovascular pharmacology mechanisms of vasorelaxation induced by the cannabidiol analogue compound O-1602 in the rat small mesenteric artery. Eur J Pharmacol 765:107–114. https://doi.org/10.1016/j.ejphar.2015.08.021 DOI PubMed
    1. Anavi-Goffer S, Baillie G, Irving AJ et al (2012) Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J Biol Chem 287:91–104 – DOI
    1. Anderson CL, Evans VF, Demarse TB et al (2017) Cannabidiol for the treatment of drug-resistant epilepsy in children: current state of research. J Pediatr Neurol 15:143–150. https://doi.org/10.1055/s-0037-1598109 DOI
    1. Bailey SJ, Sapkota RR, Golliher AE et al (2018) Lewis-acid-mediated Union of Epoxy-Carvone Diastereomers with anisole derivatives: mechanistic insight and application to the synthesis of non-natural CBD analogues. Org Lett 20:acs.orglett.8b01909. https://doi.org/10.1021/acs.orglett.8b01909 DOI

Avatar

Schaka

error: Content is protected !!
%d blogueurs aiment cette page :